| |
|
|
|
|
|
 |
| |
|
¿¡Åä¹Ìµ¥ÀÌÆ®¸®Çª·ÎÁÖ 10mL Etomidate-lipuro inj.
|
Àü¹®ÀǾàǰ | ±Þ¿© | ½Å¾à
|
|
|
¼öÀÔÀǾàǰ |
¿À³²¿ë¿ì·Á
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
Á¦Ç°º° ¿¬·É±Ý±â °í½Ã |
|
|
| ¼ººÐ¸í |
¼ººÐÄÚµå |
ƯÁ¤¿¬·É |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| etomidate |
157030BIJ |
2 ¼¼ ¹Ì¸¸ |
20090300 |
2009-12-03 |
|
|
|
 |
Á¦Ç°º° ÀӺαݱ⠰í½Ã |
|
|
|
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
| ¼ººÐ¸í |
¼ººÐÄÚµå |
±Ý±âµî±Þ |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| Etomidate |
157030BIJ |
2 |
20190131 |
20191217 |
ÀӺο¡ ´ëÇÑ ¾ÈÀü¼º ¹ÌÈ®¸³. ¼ö¼ú Áß Å¹ÝÀ» Åë°úÇÒ ¼ö ÀÖÀ½. |
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
667400511
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\4,161 ¿ø/10mL/¾ÚÇÃ(2024.07.01)(ÇöÀç¾à°¡)
\4,203 ¿ø/10mL/¾ÚÇÃ(2022.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¾ÚÇÿ¡ µç ¹é»öÀÇ À¯Á¦¼º ÁÖ»çÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
10mL/¾ÚÇÃ x 10 |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 10¹Ð¸®¸®ÅÍ |
10 ¾ÚÇÃ |
¾ÚÇÃ |
8806674005103 |
8806674005127 |
|
| 10¹Ð¸®¸®ÅÍ |
1 ¾ÚÇÃ |
¾ÚÇÃ |
8806674005103 |
8806674005110 |
|
|
| ÁÖ¼ººÐÄÚµå |
157030BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Àü½Å¸¶Ãë À¯µµÁ¦
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡Û ¼ºÀÎ : ¿¡Åä¹Ìµ¥ÀÌÆ®·Î¼ 1ȸ üÁß kg´ç 0.15¢¦0.3 mgÀ» Á¤¸ÆÅõ¿© ÇÑ´Ù.
¡Û 2¼¼ ÀÌ»ó ¾î¸°À̺ÎÅÍ 15¼¼ ÀÌÇÏÀÇ Ã»¼Ò³â ¹× °í·ÉÀÚ : ¿¡Åä¹Ìµ¥ÀÌÆ®·Î¼ 1ȸ üÁß kg´ç 0.15¢¦0.2 mgÀ» Á¤¸ÆÅõ¿© ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
¹Ýµå½Ã Á¤¸Æ Åõ¿©Çϰí ÀϹÝÀûÀ¸·Î ¼¼È÷(1ȸ Åõ¿© ½Ã°£Àº 30ÃÊ) Åõ¿©Çϰí Çʿ信 µû¶ó ºÐÇÒ Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ(ƯÈ÷, ÁöÁúÀ¯Á¦)¿¡ °ú¹Î¹ÝÀÀÀÌ Àִ ȯÀÚ
2) ½Å»ý¾Æ ¹× 2¼¼ ¹Ì¸¸ÀÇ ¿µ¡¤À¯¾Æ
3) ÇÜ(heme) »ýÇÕ¼º¿¡ Àå¾Ö°¡ Àִ ȯÀÚ(µ¿¹°½ÇÇè¿¡¼ ÀÌ ¾àÀ» Åõ¿© ½Ã Æ÷¸£ÇǸ°ÁõÀÌ ³ªÅ¸³µÀ½.)
4) ÀӺΠ|
| ½ÅÁßÅõ¿© |
1) ÁßÁõÀÇ ±äÀå ÀúÇÏ È¯ÀÚ
2) ºÎ½ÅÇÇÁú ±â´É ÀúÇÏ È¯ÀÚ
3) °£°æº¯ ȯÀÚ
4) ½Å°æÀÌ¿ÏÁ¦, ¸¶¾à, ÁøÁ¤Á¦¸¦ ÀüÅõ¿©¹ÞÀº ȯÀÚ |
| ÀÌ»ó¹ÝÀÀ |
1) ÀÌ ¾àÀº ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵åÀÇ »ýÇÕ¼ºÀ» ¾ïÁ¦ÇÑ´Ù. ÀÌ ¾à 1ȸ Åõ¿© ÈÄ ºÎ½ÅÇÇÁúÀÇ ¹ÝÀÀÀÌ ¾à 3~6½Ã°£ µ¿¾È ÇöÀúÈ÷ °¨¼ÒÇÏ¿´´Ù. ¸Å¿ì ÈçÇÏ°Ô ÄÚÆ¼¼Ö °¨¼Ò¿Í °°Àº ³»ºÐºñ°è Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ÀûÀýÇÑ Àüóġ¸¦ ¹ÞÁö ¸øÇÑ È¯ÀÚ¿¡°Ô¼ ÀÌ ¾àÀ» ´Üȸ Åõ¿© ÈÄ Á¾Á¾ °£´ë¼º±Ù°æ·ÃÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ ¼ö¸éÁ¦¿¡ ÀÇÇÑ °£´ë¼º ±Ù°æ·ÃÀº °£³ú°¡ ÈïºÐÇÏ¿© À¯¹ßµÇ¸ç ÀÌ ¾à Åõ¿© Àü¿¡ ¸¶¾à¼º ÁøÅëÁ¦(¾ÆÆíÀ¯»çÁ¦Á¦)³ª º¥Á¶µð¾ÆÁ¦ÇÉÀ» ÀüÅõ¿©ÇÏ¸é ¿¹¹æÇÒ ¼ö ÀÖ´Ù.
3) ¶§¶§·Î ÀÌ ¾àÀ» Åõ¿© ÈÄ, µ¿½Ã Åõ¿©ÇÑ ¸¶¾à¼ºÁøÅëÁ¦(¾ÆÆíÀ¯»çÁ¦Á¦) Àüóġ·Î ÀÎÇØ ±¸¿ª°ú ±¸ÅäÁõ¼¼, µå¹°°Ô ±âħ, µþ²ÚÁú, ÁøÀüÀÌ ÀϾ´Ù.
4) ÀÌ ¾àÀ» Åõ¿© ÈÄ, ¶§¶§·Î Èĵΰæ·ÃÀÌ ¹ß»ýÇß´Ù´Â º¸°í°¡ ÀÖ´Ù. ƯÈ÷ °í¿ë·®À» Åõ¿©Çϰųª ÁßÃß½Å°æ ¾ïÁ¦Á¦¿Í º´¿ëÇÏ¸é ¶§¶§·Î ´Ü½Ã°£ È£Èí¸¶ºñ°¡ ÀϾ ¼öµµ ÀÖ´Ù.
5) ¸Å¿ì µå¹°°Ô ±â°üÁö °æ·ÃÀ̳ª ¾Æ³ªÇʶô½Ã½º °°Àº ¾Ë·¹¸£±â ¹ÝÀÀ°ú °æ·ÃÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
6) ½Å°æ°è : ¶³¸², ¶§¶§·Î ¿îµ¿ÀÌ»ó, ¿ÀÇÑ, µå¹°°Ô ±Ù°£´ë°æ·Ã, ¸Å¿ì µå¹°°Ô ±äÀåÇ×Áø, ºÒ¼öÀÇÀû ±Ù¼öÃà, ¾È±¸ÁøÅÁÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) ½ÉÇ÷°ü°è : ¶§¶§·Î ¸»ÃÊÇ÷°ü ÀúÇ× °¨¼Ò·Î ÀÎÇÑ ÀϽÃÀûÀÎ Ç÷¾Ð °Çϰ¡ ÀϾ ¼ö ÀÖ´Ù. ¶ÇÇÑ µå¹°°Ô ¼¸Æ, ½ÉÀå ºÎÁ¤¸Æ, ½ÉÀå¹Úµ¿ Àå¾Ö, Á¤¸ÆÅëÁõ, ¸Å¿ì µå¹°°Ô ±â¿Ü¼öÃà, ½É½Ç±â¿Ü¼öÃà, Á¤¸Æ¿°, °íÇ÷¾ÐÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) È£Èí±â°è : µå¹°°Ô ¹«È£Èí, °úÈ£Èí, È£Èí±â°èÀÇ ÇùÂøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ°í ¸Å¿ì µå¹°°Ô ÀúÈ£Èí, µþ²ÚÁú, ±âħÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
9) ÇǺΠ: µå¹°°Ô ¹ßÁø, ¸Å¿ì µå¹°°Ô È«¹ÝÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
10) ±Ù°ñ°Ý°è : ¸Å¿ì µå¹°°Ô ±ÙÀ° °Á÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ±¹³» ½ÃÆÇ ÈÄ Á¶»ç°á°ú(Á¶»çÁõ·Ê¼ö : 632¸í) º¸°í µÈ ÀÌ»ó¹ÝÀÀÀº ´ÙÀ½°ú °°À¸¸ç, ÀÌ ¾à°úÀÇ °ü·Ã ¿©ºÎ´Â È®½ÇÇÏÁö ¾Ê´Ù : Ç÷¾Ð»ó½Â, ½É¹Ú°¨¼Ò, µ¿¼ººÎÁ¤¸Æ
|
| »óÈ£ÀÛ¿ë |
1) ½Å°æÀÌ¿ÏÁ¦, ¸¶¾à¼ºÁøÅëÁ¦(¾ÆÆíÀ¯»çÁ¦Á¦), ¾ÈÁ¤Á¦, ¾ËÄÚ¿Ã µîÀº ÀÌ ¾àÀÇ ÃÖ¸éÈ¿°ú¸¦ »ó½Â½ÃŲ´Ù.
2) ±âŸ ÁßÃ߽Űæ°è¾ïÁ¦Á¦ : ¸ð¸£ÇÉ À¯µµÃ¼(ÁøÅëÁ¦ ¹× ±âħ¾à), ÁøÁ¤Á¦, Ç׿ì¿ïÁ¦, H1 Ç×È÷½ºÅ¸¹ÎÁ¦, ¹ÙºñÃò·¹ÀÌÆ®Á¦, º¥Á¶µð¾ÆÁ¦Çɰú ±× ÀÌ¿Ü ÁøÁ¤Á¦, ½Å°æÀÌ¿ÏÁ¦, Ŭ·Î´Ïµò, ÈíÀÔ¸¶ÃëÁ¦´Â ÁßÃ߽Űæ°è ¾ïÁ¦ È¿°ú¸¦ Áõ°¡½ÃŲ´Ù.
3) ±âŸ ¸ð¸£ÇÉ À¯µµÃ¼(ÁøÅëÁ¦ ¶Ç´Â ÁøÇØÁ¦) : ƯÈ÷ °í·ÉÀÇ È¯ÀÚÀÇ °æ¿ì, ¸ð¸£ÇÉÀÇ ÁøÁ¤ È¿°ú°¡ Áõ°¡ÇÏ¿© È£ÈíÀúÇÏÀÇ À§ÇèÀÌ ÀÖ´Ù.
4) ÀÌ ¾àÀ» Åõ¿© ½Ã ¾ËÄÚ¿ÃÀÌ µé¾î°£ À½·á¸¦ º¹¿ëÇϰųª ¾ËÄÚ¿Ã ÇÔÀ¯ ¾à¹°°ú º´¿ë Åõ¿©ÇÏ´Â °ÍÀ» ÇÇÇÑ´Ù.
5) ÀÌ ¾à°ú ÆæÅ¸´ÒÀ» º´¿ë Åõ¿© ÇÒ °æ¿ì ÀÌ ¾àÀÇ ¹Ý°¨±â´Â º¯ÇÏÁö ¾Ê°í ÃÑ Ç÷Àå û¼ÒÀ²°ú ºÐÆ÷ ¿ëÀûÀÌ °¨¼ÒÇϹǷΠÀÌ ¾àÀÇ ¿ë·®À» °¨¼Ò½ÃÄÑ¾ß ÇÑ´Ù.
6) È¿¼Ò ¾ïÁ¦ ¾à¹°°ú º´¿ë Åõ¿© ½Ã ÀÌ ¾àÀÇ ÃÖ¸éÈ¿°ú¸¦ ¿¬Àå½ÃŲ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(etomidate; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Etomidate¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Etomidate binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
|
| Pharmacology |
Etomidate¿¡ ´ëÇÑ Pharmacology Á¤º¸ Etomidate is a non-barbiturate hypnotic that acts at the level of the reticular-activating system to produce anesthesia. Etomidate is an imidazole compound that appears to depress CNS function via GABA. Duration of action is intermediate between thiopental and methohexital, and recovery from a single dose is rapid with little residual depression. Like the barbiturates and propofol, etomidate is does not induce analgesia. Etomidate induces unconsciousness within one circulation time. Recovery is rapid as a result of extensive redistribution and rapid metabolism.
|
| Metabolism |
Etomidate¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cholinesterase
|
| Protein Binding |
Etomidate¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 76%, primarily to serum albumin.
|
| Half-life |
Etomidate¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 75 minutes.
|
| Biotransformation |
Etomidate¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. Metabolized rapidly by ester hydrolysis to inactive metabolites.
|
| Toxicity |
Etomidate¿¡ ´ëÇÑ Toxicity Á¤º¸ Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
|
| Drug Interactions |
Etomidate¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Etomidate¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Etomidate¿¡ ´ëÇÑ Description Á¤º¸ Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [PubChem]
|
| Dosage Form |
Etomidate¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Solution Intravenous
|
| Drug Category |
Etomidate¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anesthetics, IntravenousHypnotics and Sedatives
|
| Smiles String Canonical |
Etomidate¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCOC(=O)C1=CN=CN1C(C)C1=CC=CC=C1
|
| Smiles String Isomeric |
Etomidate¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCOC(=O)C1=CN=CN1[C@@H](C)C1=CC=CC=C1
|
| InChI Identifier |
Etomidate¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3
|
| Chemical IUPAC Name |
Etomidate¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-11-21
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. ETOMIDATE[GGT Increase][Composite Activity](Score) I(Marginal) 0(Active) 0[Alkaline Phosphatase Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGOT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGPT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[LDH Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[GGT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|